Medicus Pharma (NASDAQ:MDCX) Releases Quarterly Earnings Results, Misses Estimates By $0.50 EPS

Medicus Pharma (NASDAQ:MDCX) issued its quarterly earnings results on Wednesday. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.50), Zacks reports.

Medicus Pharma Trading Down 2.8%

MDCX traded down $0.01 during trading on Thursday, hitting $0.48. 788,602 shares of the company’s stock traded hands, compared to its average volume of 3,961,366. The company’s 50 day simple moving average is $1.01 and its two-hundred day simple moving average is $1.74. Medicus Pharma has a 12-month low of $0.37 and a 12-month high of $8.94. The stock has a market capitalization of $12.26 million, a price-to-earnings ratio of -0.22 and a beta of -1.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of Medicus Pharma during the second quarter valued at $41,000. Osaic Holdings Inc. increased its holdings in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after buying an additional 9,000 shares in the last quarter. Private Advisor Group LLC raised its position in Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after buying an additional 5,500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Medicus Pharma during the 3rd quarter valued at about $59,000. Finally, Commonwealth Equity Services LLC lifted its stake in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after acquiring an additional 17,611 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. D. Boral Capital reiterated a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a research note on Thursday, March 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $23.50.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.